MORE HETEROGENEOUS NEOINTIMAL COVERAGE AFTER EVEROLIMUS-ELUTING STENTS IMPLANTATION IN DIABETIC PATIENTS AS COMPARED TO NON-DIABETIC PATIENTS  by Okamoto, Naotaka et al.
ACC-i2 with TCT
E139
JACC March 27, 2012
Volume 59, Issue 13
MORE HETEROGENEOUS NEOINTIMAL COVERAGE AFTER EVEROLIMUS-ELUTING STENTS 
IMPLANTATION IN DIABETIC PATIENTS AS COMPARED TO NON-DIABETIC PATIENTS
i2 Poster Contributions
McCormick Place South, Hall A
Saturday, March 24, 2012, 9:30 a.m.-Noon
Session Title: Intravascular Diagnostics
Abstract Category: 13. PCI - Complex Patients, Diabetes, Renal Insufficiency
Presentation Number: 2527-548
Authors: Naotaka Okamoto, Masami Nishino, Akihiro Tanaka, Atsushi Kikuchi, Takeshi Masaki, Naoki Mori, Daisuke Nakamura, Takahiro Yoshimura, 
Yasuharu Lee, Masayuki Taniike, Nobuhiko Makino, Hiroyasu Kato, Yasuyuki Egami, Ryu Shutta, Hisaki Morita, Jun Tanouchi, Yoshio Yamada, Osaka 
Rosai Hospital, Sakai, Japan
Background: Everolimus-eluting stents (EES) revealed favorable clinical results in drug-eluting stent era, however detailed evaluation of effects of 
diabetes mellitus on neointimal coverage after EES implantation is not investigated well.
Methods: In age-matched diabetic(12 stents, 7 patients)and non-diabetic (23 stents, 15 patients)patients at 8 months after EES implantation, 
optical coherence tomography (OCT) was used to visualize 1544 and 3179 stent-struts, respectively. The OCT parameters including incidence of 
uncovered struts, malapposed struts, averaged neointimal hyperplasia thickness (NIH) and NIH% = NIH area / stent area were compared between 
diabetic and non-diabetic groups.
Results: The incidence of uncovered struts, %NIH and NIH thickness in diabetic patients were significantly higher than those in non-diabetic 
patients (a table).
Conclusions: Diabetic patients showed higher incidence of uncovered struts in spite of thicker neointimal hyperplasia which may induce more 
heterogeneous neointimal coverage as compared to non-diabetic patients.
 
